United Therapeutics Corp.

Is United Therapeutics Corp. technically bullish or bearish?

As of October 24, 2025, United Therapeutics Corp. shows a mildly bullish technical trend, with mixed indicators suggesting caution, as it has underperformed the S&P 500 recently but outperformed it year-to-date and over three years.

As of 24 October 2025, the technical trend for United Therapeutics Corp. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD also indicates bullishness. However, the weekly and monthly RSI readings are bearish, suggesting some weakness. The Bollinger Bands are mildly bullish on both weekly and monthly time frames. Daily moving averages are bullish, but the KST shows a mixed picture with weekly bullishness and monthly mild bearishness. Dow Theory indicates a mildly bearish stance weekly, but bullish monthly, and the OBV is mildly bearish weekly while bullish monthly.<BR><BR>In terms of performance, the stock has underperformed the S&P 500 over the past week and month, with returns of -3.41% and -4.60% compared to the S&P 500's gains of 1.92% and 2.32%, respectively. However, it has outperformed the benchmark year-to-date and over longer periods, with a YTD return of 18.63% versus 15.47% for the S&P 500, and a 3-year return of 88.47% compared to 78.85%. Overall, the current technical stance is mildly bullish, but with caution due to mixed indicators.

Is United Therapeutics Corp. overvalued or undervalued?

As of September 2, 2025, United Therapeutics Corp. is considered fairly valued with a P/E ratio of 19 and a PEG ratio of 0.93, showing competitive positioning in the industry and strong return performance compared to the S&P 500.

As of 2 September 2025, the valuation grade for United Therapeutics Corp. has moved from very attractive to attractive, indicating a shift in its perceived value. The company appears to be fairly valued at this time. Key valuation ratios include a P/E ratio of 19, an EV to EBITDA of 13.67, and a PEG ratio of 0.93, which suggest that the stock is reasonably priced relative to its earnings growth potential.<BR><BR>In comparison to its peers, United Therapeutics Corp. has a higher P/E ratio than Incyte Corp. (22.95) but lower than Royalty Pharma Plc (12.26), indicating a competitive positioning within the industry. Additionally, the company's return performance has outpaced the S&P 500 across multiple periods, with a 1-month return of 30.49% compared to the S&P 500's 2.33%, reinforcing the attractiveness of the stock in the current market environment.

How big is United Therapeutics Corp.?

As of Jun 18, United Therapeutics Corp. has a market capitalization of $20.58 billion, with net sales of $2.99 billion and a net profit of $1.21 billion over the latest four quarters.

Market Cap: As of Jun 18, United Therapeutics Corp. has a market capitalization of 20,576.71 million, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, United Therapeutics Corp. reported net sales of 2,994.10 million and a net profit of 1,210.70 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 6,444.00 million and total assets of 7,438.40 million.

What does United Therapeutics Corp. do?

United Therapeutics Corporation is a biotechnology company that develops and commercializes treatments for chronic and life-threatening conditions, with recent net sales of $794 million and a market cap of approximately $20.58 billion. Key financial metrics include a P/E ratio of 19.00 and a return on equity of 17.79%.

Overview:<BR>United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions, operating within the Pharmaceuticals & Biotechnology industry and classified as a mid-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 794 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 322 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 20,576.71 Million (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: 19.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.46 <BR>Return on Equity: 17.79% <BR>Price to Book: 3.02<BR><BR>Contact Details:<BR>Address: 1040 SPRING ST, SILVER SPRING MD: 20910 <BR>Tel: 1 301 6089292 <BR>Fax: 1 301 6089291 <BR>Website: http://www.unither.com

Should I buy, sell or hold United Therapeutics Corp.?

Who are in the management team of United Therapeutics Corp.?

As of March 2022, the management team of United Therapeutics Corp. includes Dr. Martine Rothblatt as Chairman and CEO, Prof. Christopher Patusky as Lead Independent Vice Chairman, and several directors including Dr. Linda Maxwell and independent members like Mr. Christopher Causey and Prof. Raymond Dwek.

As of March 2022, the management team of United Therapeutics Corp. includes Dr. Martine Rothblatt, who serves as the Chairman of the Board and Chief Executive Officer. Other members of the board include Prof. Christopher Patusky as the Lead Independent Vice Chairman, Dr. Linda Maxwell as a Director, and several Independent Directors: Mr. Christopher Causey, Prof. Raymond Dwek, Mr. Richard Giltner, and Prof. Katherine Klein.